IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total value of $2,764,980.00. Following the completion of the transaction, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at approximately $163,529,058.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $154.88 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $113.47 and a 52 week high of $173.01. The firm has a market capitalization of $13,508.48, a PE ratio of 52.15, a P/E/G ratio of 2.34 and a beta of 0.46. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The business had revenue of $492.00 million during the quarter, compared to analysts’ expectations of $492.94 million. During the same quarter last year, the business posted $0.62 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. equities analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://stocknewstimes.com/2017/11/19/insider-selling-idexx-laboratories-inc-idxx-ceo-sells-2764980-00-in-stock.html.
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in IDEXX Laboratories by 4.0% during the second quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock valued at $1,495,488,000 after buying an additional 354,024 shares in the last quarter. BlackRock Inc. boosted its stake in IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after buying an additional 673,347 shares in the last quarter. Koch Industries Inc. boosted its stake in IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after buying an additional 1,396,113 shares in the last quarter. Renaissance Technologies LLC boosted its stake in IDEXX Laboratories by 38.6% during the second quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock valued at $218,224,000 after buying an additional 376,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after buying an additional 392,790 shares in the last quarter. 88.03% of the stock is owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on the company. BidaskClub cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Friday, July 28th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $173.67.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.